Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302

Por Weiss, Glen J., Lewandowski, Karen, Oneall, Jon, Kroll, Stew
Publicado em 2011

AT-12 PHASE 1/2 STUDY OF TH-302, INVESTIGATIONAL HYPOXIA-ACTIVATED PRODRUG, AND BEVACIZUMAB IN PATIENTS WITH BEVACIZUMAB-REFRACTORY RECURRENT GLIOBLASTOMA

Por Brenner, Andrew, Floyd, John, Eng, Clarence, Kroll, Stew, Fichtel, Lisa, Gruslova, Aleksandra, Lodi, Alessia, Tiziani, Stefano
Publicado em 2014

Phase II Study of the Safety and Antitumor Activity of the Hypoxia-Activated Prodrug TH-302 in Combination With Doxorubicin in Patients With Advanced Soft Tissue Sarcoma

Por Chawla, Sant P., Cranmer, Lee D., Van Tine, Brian A., Reed, Damon R., Okuno, Scott H., Butrynski, James E., Adkins, Douglas R., Hendifar, Andrew E., Kroll, Stew, Ganjoo, Kristen N.
Publicado no J Clin Oncol (2014)

A Phase I Study of Evofosfamide, an Investigational Hypoxia-Activated Prodrug, in Patients with Advanced Leukemia

Por Badar, Talha, Handisides, Damian R., Benito, Juliana M., Richie, Mary Ann, Borthakur, Gautam, Jabbour, Elias, Harutyunyan, Karine, Konoplev, Sergej, Faderl, Stefan, Kroll, Stew, Andreeff, Michael, Pearce, Tillman, Kantarjian, Hagop M., Cortes, Jorge E., Thomas, Deborah A., Konopleva, Marina
Publicado no Am J Hematol (2016)

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer

Por Borad, Mitesh J., Reddy, Shantan G., Bahary, Nathan, Uronis, Hope E., Sigal, Darren, Cohn, Allen L., Schelman, William R., Stephenson, Joe, Chiorean, E. Gabriela, Rosen, Peter J., Ulrich, Brian, Dragovich, Tomislav, Del Prete, Salvatore A., Rarick, Mark, Eng, Clarence, Kroll, Stew, Ryan, David P.
Publicado no J Clin Oncol (2015)